New combo therapy aims to help patients with rare blood disease stop steroids
NCT ID NCT07518277
First seen Apr 09, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study looks at whether adding sirolimus to standard steroid treatment helps adults with newly diagnosed mild autoimmune hemolytic anemia (AIHA) achieve long-term remission without needing ongoing medication. About 216 participants will be randomly assigned to receive either steroids alone or steroids plus sirolimus for 6 months, then followed for 24 months. The main goal is to see if more people in the combo group can stop steroids and stay in remission at 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA, AIHA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
Conditions
Explore the condition pages connected to this study.